Cache Advisors LLC Raises Holdings in Johnson & Johnson $JNJ

Posted by Donald Scott on Jun 26th, 2026

Cache Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 61.0% in the 1st quarter, Holdings Channel reports. The firm owned 15,428 shares of the company’s stock after acquiring an additional 5,843 shares during the period. Johnson & Johnson accounts for 0.4% of Cache Advisors LLC’s portfolio, making the stock its 18th biggest holding. Cache Advisors LLC’s holdings in Johnson & Johnson were worth $3,771,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Brighton Jones LLC lifted its stake in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. United Bank boosted its holdings in shares of Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after acquiring an additional 692 shares during the period. Wealth Group Ltd. raised its holdings in shares of Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. lifted its position in Johnson & Johnson by 9.8% during the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after purchasing an additional 6,584 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 1.6%

Shares of JNJ stock opened at $244.93 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The company has a market cap of $589.61 billion, a price-to-earnings ratio of 28.32, a PEG ratio of 2.36 and a beta of 0.26. Johnson & Johnson has a 1 year low of $151.01 and a 1 year high of $251.71. The firm has a fifty day moving average price of $230.60 and a 200-day moving average price of $229.25.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were paid a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.2%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 61.97%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on JNJ shares. Argus raised their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Barclays boosted their target price on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 15th. Morgan Stanley set a $283.00 price target on Johnson & Johnson in a research note on Wednesday, April 15th. Daiwa Securities Group lifted their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a report on Thursday, April 16th. Finally, The Goldman Sachs Group upped their price objective on Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.04.

View Our Latest Stock Analysis on JNJ

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson was highlighted as a top dividend-safe name, with multiple articles arguing that its reliable cash flows and long dividend track record make it an attractive holding for income-focused investors. One Stock to Own For Ultimate Dividend Safety
Positive Sentiment: The company advanced its cardiac ablation technology in Europe with the availability of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a reminder that JNJ continues to expand its medtech portfolio and commercial reach. Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform
Neutral Sentiment: Analysts are looking for a single-digit earnings increase when Johnson & Johnson reports second-quarter results in July, which suggests stable but not explosive near-term growth expectations. Johnson & Johnson Earnings Preview: What to Expect
Neutral Sentiment: Recent market commentary also noted JNJ rising while broader markets dipped, indicating investor preference for defensive stocks rather than a company-specific catalyst. Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.